How does Edluar compare to Ambien for treating insomnia. What are the key differences between sublingual and oral zolpidem formulations. Which medication works faster for sleep induction. What do clinical studies reveal about their efficacy and side effects.

Overview of Edluar and Ambien for Insomnia Treatment

Edluar and Ambien are both brand names for the drug zolpidem, which is commonly prescribed to treat insomnia. While they contain the same active ingredient, there are some key differences between these two medications:

• Edluar is a sublingual tablet that dissolves under the tongue
• Ambien is an oral tablet that is swallowed
• Edluar may work faster due to its sublingual formulation
• Ambien is available in immediate-release and controlled-release versions

Understanding these differences can help patients and healthcare providers determine which formulation may be most appropriate for individual cases of insomnia.

Efficacy of Edluar Based on Patient Reviews

According to reviews on Drugs.com, Edluar has received very positive feedback from patients using it to treat insomnia:

• Average rating of 9.2 out of 10 from 12 reviews
• 92% of reviewers reported a positive experience
• 0% reported a negative experience
• 58% gave it a perfect 10/10 rating

This high level of patient satisfaction suggests that many users find Edluar to be an effective treatment for their insomnia symptoms. However, it’s important to note that individual experiences may vary.

Comparing Sleep Induction: Edluar vs Ambien

A key factor in evaluating insomnia medications is how quickly they help patients fall asleep. A randomized, double-blind study compared the sleep induction effects of sublingual zolpidem (Edluar) 10 mg versus oral zolpidem (Ambien) 10 mg using polysomnography in patients with primary insomnia.

The study found that sublingual zolpidem (Edluar) significantly outperformed oral zolpidem (Ambien) in several measures of sleep induction:

• Latency to persistent sleep (LPS) was shortened by 34% or 10.3 minutes
• Sleep onset latency (SOL) was reduced
• Latency to stage 1 sleep (ST1L) was decreased

These results suggest that the sublingual formulation of Edluar may help patients fall asleep more quickly compared to the traditional oral tablet form of Ambien.

Mechanism of Action: How Edluar and Ambien Work

Both Edluar and Ambien contain zolpidem, which belongs to a class of drugs called sedative-hypnotics. Zolpidem works by enhancing the effects of GABA, a neurotransmitter that promotes sleep and relaxation in the brain.

The key difference lies in the method of delivery:

• Edluar’s sublingual formulation allows for rapid absorption through the blood vessels under the tongue
• Ambien’s oral tablet is absorbed through the digestive system

This difference in absorption may account for Edluar’s faster onset of action in some patients. However, both medications ultimately work through the same mechanism to induce sleep.

Side Effects and Safety Considerations

While Edluar and Ambien are generally well-tolerated, they can cause side effects and carry certain risks. Common side effects may include:

• Daytime drowsiness
• Dizziness
• Headache
• Nausea
• Confusion

More serious concerns include:

• Risk of dependence and withdrawal symptoms with long-term use
• Potential for complex sleep behaviors (e.g., sleep-walking, sleep-driving)
• Increased risk of falls, especially in older adults

Patients should discuss these risks with their healthcare provider and follow prescribed dosing instructions carefully. It’s also important to avoid alcohol and other central nervous system depressants while taking these medications.

Dosage and Administration Guidelines

Proper administration is crucial for the safe and effective use of Edluar and Ambien:

Edluar (Sublingual Zolpidem):

• Typical dose: 5 mg for women, 5-10 mg for men
• Place tablet under tongue and allow to dissolve completely
• Do not swallow or take with water
• Take immediately before bedtime

Ambien (Oral Zolpidem):

• Typical dose: 5 mg for women, 5-10 mg for men
• Swallow tablet whole with water
• Take immediately before bedtime
• Extended-release version available for those who have trouble staying asleep

In both cases, patients should have at least 7-8 hours available for sleep after taking the medication to avoid next-day impairment.

Long-term Use and Alternatives for Chronic Insomnia

While Edluar and Ambien can be effective for short-term insomnia treatment, long-term use raises concerns about dependence and tolerance. For chronic insomnia, healthcare providers may recommend alternative approaches:

• Cognitive Behavioral Therapy for Insomnia (CBT-I)
• Sleep hygiene improvements
• Relaxation techniques
• Other classes of sleep medications (e.g., melatonin receptor agonists, orexin receptor antagonists)

Patients with persistent insomnia should work closely with their healthcare provider to develop a comprehensive treatment plan that addresses underlying causes and promotes long-term sleep health.

Patient Considerations When Choosing Between Edluar and Ambien

When deciding between Edluar and Ambien, patients and healthcare providers should consider several factors:

• Speed of onset: Edluar may work faster due to sublingual absorption
• Duration of effect: Ambien CR (controlled-release) may be better for those who wake up during the night
• Ease of administration: Some patients may prefer sublingual tablets, while others find oral tablets easier to take
• Cost and insurance coverage: Availability and pricing can vary between formulations
• Individual response: Some patients may respond better to one formulation over the other

Ultimately, the choice between Edluar and Ambien should be made in consultation with a healthcare provider, taking into account the patient’s specific sleep issues, medical history, and personal preferences.

In conclusion, both Edluar and Ambien offer effective treatment options for insomnia, with Edluar potentially providing faster sleep induction due to its sublingual formulation. However, as with all sleep medications, they should be used judiciously and in combination with good sleep hygiene practices for optimal results. Patients experiencing chronic insomnia should explore comprehensive treatment approaches that address underlying causes and promote long-term sleep health.

Edluar for Insomnia Reviews – Drugs.com

Print

Save

Edluar
has an average rating of 9.2 out of 10 from a total of 12 reviews
for the
treatment of Insomnia.
92% of reviewers reported a positive experience, while 0% reported a negative experience.

Edluar rating summary

9.2/10 average rating

12 ratings from 13 user reviews.

Compare all 83 medications used in the treatment of Insomnia.

Reviews for Edluar

Frequently asked questions

• Quviviq vs. Ambien: How do they compare?
• Ambien: What are 11 Things You Need to Know?
• Why am I unable to sleep after taking Ambien?
• Is Ambien safe for long-term use?

Are you taking this medicine?

• Add your review
• Learn more about Edluar

More FAQ

• Is Ambien a benzo?
• Is Ambien addictive?
• What is this pill? Tannish peach color, elliptical, marked 10 MG and 5 dots in a small box?
• What is the half life of Ambien?

Reviews may be edited to correct grammar/spelling or to remove inappropriate language and content. Reviews that appear to be created by parties with a vested interest are not published. This information is not intended to endorse any particular medication. While these reviews may be helpful, they are not a substitute for the expertise, knowledge, and judgement of healthcare professionals.

Learn more about Insomnia

• Anticholinergic Drugs to Avoid in the Elderly
• Benzodiazepines: Overview and Use
• Sleep (Insomnia) Medications and Alcohol Interactions

Care guides

• Insomnia

Symptoms and treatments

• Insomnia

Medicine.

com guides (external)

• Insomnia Guide

More about Edluar (zolpidem)

• Check interactions
• Compare alternatives
• Pricing & coupons
• Drug images
• Latest FDA alerts (4)
• Side effects
• Dosage information
• During pregnancy
• Generic availability
• FDA approval history
• Drug class: miscellaneous anxiolytics, sedatives and hypnotics
• Breastfeeding
• En español

Patient resources

• Drug Information

Other brands

Ambien, Ambien CR, Zolpimist, Intermezzo

Professional resources

• Prescribing Information

Related treatment guides

• Insomnia

Sublingual zolpidem in early onset of sleep compared to oral zolpidem: polysomnographic study in patients with primary insomnia

Randomized Controlled Trial

. 2010 Jun;26(6):1423-31.

doi: 10. 1185/03007991003788225.

Corinne Staner 
¹
, Frédéric Joly, Nathalie Jacquot, Irina D Vlasova, Maria Nehlin, Thomas Lundqvist, Charlotte Edenius, Luc Staner

Affiliations

Affiliation

• ¹ Forenap Pharma, Rouffach, France.

• PMID:

  20397964

• DOI:

  10.1185/03007991003788225

Randomized Controlled Trial

Corinne Staner et al.

Curr Med Res Opin.

2010 Jun.

. 2010 Jun;26(6):1423-31.

doi: 10.1185/03007991003788225.

Authors

Corinne Staner 
¹
, Frédéric Joly, Nathalie Jacquot, Irina D Vlasova, Maria Nehlin, Thomas Lundqvist, Charlotte Edenius, Luc Staner

Affiliation

• ¹ Forenap Pharma, Rouffach, France.

• PMID:

  20397964

• DOI:

  10.1185/03007991003788225

Abstract

Objective:

To compare the hypnotic effects of a single dose of a sublingual formulation of zolpidem (Edluar*) 10 mg vs oral formulation (Ambien dagger ) 10 mg by polysomnography (PSG) in DSM-IV primary insomnia patients. Primary objective was to compare the two formulations on sleep induction, measured by latency to persistent sleep (LPS), sleep onset latency (SOL) and latency to stage 1 (ST1L).

Research and methods:

This was a randomized, double-blind, two-period, cross-over multi-centre study in which each period comprised two successive PSG recording nights. Treatment was administered when PSG recordings started. Subjective sleep and residual effects were assessed the next morning.

Results:

Seventy female and male patients aged 19-64 were analysed. Sublingual zolpidem significantly shortened LPS by 34% or 10.3 minutes as compared to oral zolpidem (95% CI: -4.3 min to -16.2 min, p = 0.001). SOL and ST1L were also significantly shortened (p < 0.01). Furthermore the two formulations were comparable in terms of sleep maintenance properties based on total sleep time (TST). The improvement in subjective sleep and next-day residual effects did not differ between the two treatments. Both routes of administration were well tolerated.

Conclusions:

The results demonstrate that sublingual zolpidem is superior to an equivalent dose of oral zolpidem in terms of sleep inducing properties in a carefully selected sample of primary insomnia patients.

Similar articles

• Sublingual zolpidem (Edluar™; Sublinox™).

  Yang LP, Deeks ED.

  Yang LP, et al.
  CNS Drugs. 2012 Nov;26(11):1003-10. doi: 10.1007/s40263-012-0009-y.
  CNS Drugs. 2012.

  PMID: 23034583

  Review.

• Sublingual zolpidem is more effective than oral zolpidem in initiating early onset of sleep in the post-nap model of transient insomnia: a polysomnographic study.

  Staner L, Eriksson M, Cornette F, Santoro F, Muscat N, Luthinger R, Roth T.

  Staner L, et al.
  Sleep Med. 2009 Jun;10(6):616-20. doi: 10.1016/j.sleep.2008.06.008. Epub 2008 Nov 8.
  Sleep Med. 2009.

  PMID: 18996742

  Clinical Trial.

• Efficacy and safety of zolpidem-MR: a double-blind, placebo-controlled study in adults with primary insomnia.

  Roth T, Soubrane C, Titeux L, Walsh JK; Zoladult Study Group.

  Roth T, et al.
  Sleep Med. 2006 Aug;7(5):397-406. doi: 10.1016/j.sleep.2006.04.008. Epub 2006 Jul 3.
  Sleep Med. 2006.

  PMID: 16815744

  Clinical Trial.

• Lower doses of sublingual Zolpidem are more effective than oral Zolpidem to anticipate sleep onset in healthy volunteers.

  Valente KD, Hasan R, Tavares SM, Gattaz WF.

  Valente KD, et al.
  Sleep Med. 2013 Jan;14(1):20-3. doi: 10.1016/j.sleep.2012.09.003. Epub 2012 Dec 4.
  Sleep Med. 2013.

  PMID: 23218533

  Clinical Trial.

• A new sublingual formulation of zolpidem for the treatment of sleep-onset insomnia.

  Staner L, Danjou P, Luthringer R.

  Staner L, et al.
  Expert Rev Neurother. 2012 Feb;12(2):141-53. doi: 10.1586/ern.11.197.
  Expert Rev Neurother. 2012.

  PMID: 22288669

  Review.

See all similar articles

Cited by

• Sublingual and oral zolpidem for insomnia disorder: a 3-month randomized trial.

  Castro LS, Otuyama LJ, Fumo-Dos-Santos C, Tufik S, Poyares D.

  Castro LS, et al.
  Braz J Psychiatry. 2020 Apr;42(2):175-184. doi: 10.1590/1516-4446-2019-0389. Epub 2019 Dec 20.
  Braz J Psychiatry. 2020.

  PMID: 31859791
  Free PMC article.

  Clinical Trial.

• Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline.

  Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL.

  Sateia MJ, et al.